{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:34:26Z","timestamp":1789450466509,"version":"build-2803163510"},"reference-count":41,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acquired T-cell dysfunction is characteristic of chronic lymphocytic leukemia (CLL) and is associated with reduced efficacy of T cell\u2013based therapies. A recently described feature of dysfunctional CLL-derived CD8 T cells is reduced metabolic plasticity. To what extend CD4 T cells are affected and whether CD4 T-cell metabolism and function can be restored upon clinical depletion of CLL cells are currently unknown. We address these unresolved issues by comprehensive phenotypic, metabolic, transcriptomic, and functional analysis of CD4 T cells of untreated patients with CLL and by analysis of the effects of venetoclax plus obinutuzumab on the CD4 population. Resting CD4 T cells derived from patients with CLL expressed lower levels of GLUT-1 and displayed deteriorated oxidative phosphorylation (OXPHOS) and overall reduced mitochondrial fitness. Upon T-cell stimulation, CLL T cells were unable to initiate glycolysis. Transcriptome analysis revealed that depletion of CLL cells in\u00a0vitro resulted in upregulation of OXPHOS and glycolysis pathways and restored T-cell function in\u00a0vitro. Analysis of CD4 T cells from patients with CLL before and after venetoclax plus obinutuzumab treatment, which led to effective clearance of CLL in blood and bone marrow, revealed recovery of T-cell activation and restoration of the switch to glycolysis, as well as improved T-cell proliferation. Collectively, these data demonstrate that CLL cells impose metabolic restrictions on CD4 T cells, which leads to reduced CD4 T-cell functionality. This trial was registered in the Netherlands Trial Registry as #NTR6043.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007034","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T20:55:12Z","timestamp":1652820912000},"page":"4185-4195","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0636-6754","authenticated-orcid":false,"given":"J. A. C.","family":"van Bruggen","sequence":"first","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam,"},{"name":"2Lymphoma and Myeloma Center Amsterdam, and"},{"name":"3Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, University of Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J. W.","family":"van der Windt","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam,"},{"name":"2Lymphoma and Myeloma Center Amsterdam, and"},{"name":"3Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, University of Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hoogendoorn","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Dubois","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam,"},{"name":"2Lymphoma and Myeloma Center Amsterdam, and"},{"name":"3Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, University of Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":false,"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam,"},{"name":"2Lymphoma and Myeloma Center Amsterdam, and"},{"name":"3Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, University of Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-315X","authenticated-orcid":false,"given":"F. S.","family":"Peters","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam,"},{"name":"2Lymphoma and Myeloma Center Amsterdam, and"},{"name":"3Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, University of Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"issue":"25","key":"2022071915272018600_B1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood."},{"key":"2022071915272018600_B2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-pathol-020712-163955","article-title":"The pathogenesis of chronic lymphocytic leukemia","volume":"9","author":"Zhang","year":"2014","journal-title":"Annu Rev Pathol."},{"issue":"1","key":"2022071915272018600_B3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.intimp.2013.05.021","article-title":"Tumor-induced host immunosuppression: special focus on CLL","volume":"17","author":"Cutucache","year":"2013","journal-title":"Int Immunopharmacol."},{"issue":"1","key":"2022071915272018600_B4","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2012.165","article-title":"Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function","volume":"27","author":"DiLillo","year":"2013","journal-title":"Leukemia."},{"issue":"9","key":"2022071915272018600_B5","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood."},{"issue":"5","key":"2022071915272018600_B6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2013-08-518183","article-title":"CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia","volume":"123","author":"te Raa","year":"2014","journal-title":"Blood."},{"issue":"1","key":"2022071915272018600_B7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy","volume":"134","author":"van Bruggen","year":"2019","journal-title":"Blood."},{"issue":"7","key":"2022071915272018600_B8","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest."},{"issue":"9","key":"2022071915272018600_B9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1084\/jem.20151159","article-title":"T cell metabolism drives immunity","volume":"212","author":"Buck","year":"2015","journal-title":"J Exp Med."},{"issue":"6","key":"2022071915272018600_B10","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell."},{"issue":"6","key":"2022071915272018600_B11","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.4049\/jimmunol.1502464","article-title":"Suppression of Glut1 and glucose metabolism by decreased Akt\/mTORC1 signaling drives T cell impairment in B cell leukemia","volume":"197","author":"Siska","year":"2016","journal-title":"J Immunol."},{"issue":"12","key":"2022071915272018600_B12","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.3390\/cancers12123837","article-title":"Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-Hodgkin lymphoma","volume":"12","author":"van Bruggen","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"8","key":"2022071915272018600_B13","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41375-020-0873-2","article-title":"T-cells in chronic lymphocytic leukemia: guardians or drivers of disease?","volume":"34","author":"Roessner","year":"2020","journal-title":"Leukemia."},{"issue":"5","key":"2022071915272018600_B14","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3324\/haematol.2020.267914","article-title":"T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective","volume":"106","author":"Peters","year":"2021","journal-title":"Haematologica."},{"issue":"17","key":"2022071915272018600_B15","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv."},{"issue":"4","key":"2022071915272018600_B16","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J Immunol."},{"issue":"8","key":"2022071915272018600_B17","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest."},{"issue":"4","key":"2022071915272018600_B18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022071915272018600_B19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-014-0340-3","article-title":"Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia","volume":"75","author":"Hoy","year":"2015","journal-title":"Drugs."},{"issue":"3","key":"2022071915272018600_B20","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(22)00034-5","article-title":"Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139\/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial","volume":"9","author":"Kersting","year":"2022","journal-title":"Lancet Haematol."},{"issue":"3","key":"2022071915272018600_B21","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1182\/blood-2003-01-0182","article-title":"Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia","volume":"102","author":"Mackus","year":"2003","journal-title":"Blood."},{"key":"2022071915272018600_B22","doi-asserted-by":"crossref","first-page":"3.16B.1","DOI":"10.1002\/0471142735.im0316bs113","article-title":"Measuring bioenergetics in T cells using a Seahorse Extracellular Flux Analyzer","volume":"113","author":"van der Windt","year":"2016","journal-title":"Curr Protoc Immunol."},{"issue":"1","key":"2022071915272018600_B23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics."},{"key":"2022071915272018600_B24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics."},{"issue":"12","key":"2022071915272018600_B25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"1","key":"2022071915272018600_B26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cmet.2014.05.004","article-title":"The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function","volume":"20","author":"Macintyre","year":"2014","journal-title":"Cell Metab."},{"issue":"1","key":"2022071915272018600_B27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cmet.2015.11.002","article-title":"Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy","volume":"23","author":"Sukumar","year":"2016","journal-title":"Cell Metab."},{"issue":"1","key":"2022071915272018600_B28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","article-title":"Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development","volume":"36","author":"van der Windt","year":"2012","journal-title":"Immunity."},{"issue":"7","key":"2022071915272018600_B29","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood."},{"issue":"24","key":"2022071915272018600_B30","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1182\/bloodadvances.2018019422","article-title":"Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL","volume":"2","author":"Kater","year":"2018","journal-title":"Blood Adv."},{"issue":"3","key":"2022071915272018600_B31","first-page":"677","article-title":"Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia","volume":"20","author":"Giannopoulos","year":"2008","journal-title":"Oncol Rep."},{"issue":"2","key":"2022071915272018600_B32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/07357907.2012.756110","article-title":"Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression","volume":"31","author":"Jadidi-Niaragh","year":"2013","journal-title":"Cancer Invest."},{"issue":"5","key":"2022071915272018600_B33","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3109\/10428194.2012.728287","article-title":"Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias","volume":"54","author":"Lad","year":"2013","journal-title":"Leuk Lymphoma."},{"key":"2022071915272018600_B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2015.00001","article-title":"Glucose metabolism regulates T cell activation, differentiation, and functions","volume":"6","author":"Palmer","year":"2015","journal-title":"Front Immunol."},{"key":"2022071915272018600_B35","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-152495","article-title":"Chronic lymphocytic leukemia actively induces T-cell dysfunction by contact-dependent signaling via CD24 and CD52","volume":"138","author":"Van Bruggen","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2022071915272018600_B36","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","article-title":"Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial","volume":"34","author":"Herling","year":"2020","journal-title":"Leukemia."},{"issue":"1","key":"2022071915272018600_B37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hon.2900060103","article-title":"Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation","volume":"6","author":"Shustik","year":"1988","journal-title":"Hematol Oncol."},{"issue":"8","key":"2022071915272018600_B38","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41419-020-02867-2","article-title":"Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition","volume":"11","author":"Roca-Portoles","year":"2020","journal-title":"Cell Death Dis."},{"issue":"12","key":"2022071915272018600_B39","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med."},{"issue":"1","key":"2022071915272018600_B40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov."},{"issue":"6","key":"2022071915272018600_B41","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/imt-2017-0147","article-title":"Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia","volume":"10","author":"Garc\u00eda-Mu\u00f1oz","year":"2018","journal-title":"Immunotherapy."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4185\/1907989\/advancesadv2022007034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4185\/1907989\/advancesadv2022007034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T11:58:39Z","timestamp":1675598319000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/14\/4185\/485285\/Depletion-of-CLL-cells-by-venetoclax-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":41,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007034","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]}}}